KRAS and pancreatic neoplasm: As 97% pancreatic cancer cells carry activating mutations in Kras, and at least 50% have mutated p53 tumor suppressor, it is predicted that such mutations and commensurate oncogenic events contribute to overexpression of the glycolytic genes.